NCT06950814

Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma

Prognostic Impact of Adjuvant Therapy Following Surgical Resection in Primary Hepatic Sarcomatoid Carcinoma: A Retrospective Cohort Study

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: West China Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.

Conditions

• Sarcomatoid Carcinoma
• Liver Cancer
• Adjuvant Therapy

Interventions

Type	Name	Description
PROCEDURE	postoperative adjuvant therapy	Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.

Timeline

• Start date: 2025-04-05
• Primary completion: 2025-05-03
• Completion: 2025-05-05
• First posted: 2025-04-30
• Last updated: 2025-04-30

Locations

1 site across 1 country: China